Skip to main content

Advertisement

Table 1 Patient characteristics at time of starting tenofovir

From: Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: A comparative cohort analysis between Western India and United Kingdom

   Royal Free Pune
N   574 (100.0) 708 (100.0)
Age (years) Median (IQR) 41 (35, 47) 38 (34, 45)
Gender Male 439 (76.5) 537 (75.8)
  Female 135 (23.5) 171 (24.2)
Ethnicity White 339 (59.1) -
  Black 161 (28.1) -
  Indian - 708 (100.0)
  Other 74 (12.9) -
Risk for HIV transmission MSM 333 (58.0) -
Heterosexual 224 (39.0) -
  Other 17 (3.0) -
CD4 count (cells/mm3) Median (IQR) 348 (230, 525) N = 571 242 (118, 395) N = 657
HIV RNA viral load (log copies/ml) Median (IQR) 4.2 (<1.7, 5.0) N = 536 N/A
ART-naïve when started TDF Yes 314 (54.7) 307 (43.4)
No 260 (45.3) 401 (56.6)
Time since first ART at time of starting TDF (weeks) Median (IQR) 368 (217, 545) N = 260 162 (66, 274) N = 400
Other ARVs in regimen Emtricitabine 530 (97.2) 641 (90.5)
  Lamivudine 28 (4.9) 61 (8.6)
  Zidovudine 10 (1.7) 62 (8.8)
  Didanosine 1 (0.2) 1 (0.1)
  Abacavir 22 (3.8) 2 (0.2)
  Lopinavir 152 (26.5) 49 (6.9)
  Atazanavir 88 (15.3) 125 (17.7)
  Darunavir 35 (6.1) 0 (0.0)
  Saquinavir 28 (4.9) 1 (0.1)
  Fos-amprenavir 16 (2.8) 0 (0.0)
  Nelfinavir 2 (0.4) 0 (0.0)
  Ritonavir 308 (53.6) 181 (25.6)
  Efavirenz 211 (36.8) 341 (48.2)
  Nevirapine 50 (8.7) 183 (25.9)
  Etravirine 7 (1.2) 0 (0.0)
  T20 1 (0.2) 0 (0.0)
  Raltegravir 13 (2.3) 0 (0.0)
  Maraviroc 2 (0.4) 0 (0.0)
  Stavudine   13 (1.8)
  Indinavir   6 (0.9)
Baseline eGFR Median (IQR) 102 (89, 117) 100 (82, 119)
Baseline creatinine Median (IQR) 77 (68, 87) 79 (62, 88)